Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(4.55)
# 260
Out of 5,130 analysts
118
Total ratings
53.7%
Success rate
25.72%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FBLG FibroBiologics | Reiterates: Buy | $5 | $0.34 | +1,379.29% | 8 | Jan 2, 2026 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $6 | $1.52 | +294.74% | 3 | Dec 2, 2025 | |
| KOD Kodiak Sciences | Maintains: Buy | $24 → $26 | $27.72 | -6.20% | 7 | Nov 17, 2025 | |
| IMUX Immunic | Maintains: Buy | $10 → $8 | $0.66 | +1,103.19% | 6 | Nov 14, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $52 → $56 | $33.37 | +67.82% | 13 | Nov 12, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $20 → $26 | $15.02 | +73.16% | 11 | Oct 31, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Buy | $30 → $44 | $16.08 | +173.63% | 5 | Oct 28, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $72 → $88 | $76.87 | +14.48% | 2 | Oct 20, 2025 | |
| DMAC DiaMedica Therapeutics | Reiterates: Buy | $12 | $8.16 | +47.06% | 7 | Aug 15, 2025 | |
| LYRA Lyra Therapeutics | Reiterates: Neutral | $16 | $3.77 | +324.74% | 9 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $56 | $14.87 | +276.60% | 7 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $1.93 | +314.51% | 4 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $10 | $7.74 | +29.20% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $4.11 | +143.31% | 13 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $18.49 | +73.07% | 3 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $7.50 | +380.00% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $447.23 | -93.74% | 1 | Aug 22, 2023 |
FibroBiologics
Jan 2, 2026
Reiterates: Buy
Price Target: $5
Current: $0.34
Upside: +1,379.29%
Akebia Therapeutics
Dec 2, 2025
Reiterates: Buy
Price Target: $6
Current: $1.52
Upside: +294.74%
Kodiak Sciences
Nov 17, 2025
Maintains: Buy
Price Target: $24 → $26
Current: $27.72
Upside: -6.20%
Immunic
Nov 14, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $0.66
Upside: +1,103.19%
Mineralys Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $52 → $56
Current: $33.37
Upside: +67.82%
Phathom Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $20 → $26
Current: $15.02
Upside: +73.16%
Zenas BioPharma
Oct 28, 2025
Maintains: Buy
Price Target: $30 → $44
Current: $16.08
Upside: +173.63%
Tarsus Pharmaceuticals
Oct 20, 2025
Maintains: Buy
Price Target: $72 → $88
Current: $76.87
Upside: +14.48%
DiaMedica Therapeutics
Aug 15, 2025
Reiterates: Buy
Price Target: $12
Current: $8.16
Upside: +47.06%
Lyra Therapeutics
Aug 14, 2025
Reiterates: Neutral
Price Target: $16
Current: $3.77
Upside: +324.74%
Aug 1, 2025
Maintains: Buy
Price Target: $48 → $56
Current: $14.87
Upside: +276.60%
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $1.93
Upside: +314.51%
Jun 18, 2025
Assumes: Buy
Price Target: $10
Current: $7.74
Upside: +29.20%
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $4.11
Upside: +143.31%
May 12, 2025
Reiterates: Buy
Price Target: $32
Current: $18.49
Upside: +73.07%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $7.50
Upside: +380.00%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $447.23
Upside: -93.74%